These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20870278)

  • 1. M-AAA-thrombin: potent anticoagulant and antiplatelet thrombin derivative with differential affinity for factor VIII and PAR1.
    Hosokawa K; Matsuda H; Ohnishi T; Gonda M; Koide T
    Thromb Res; 2010 Nov; 126(5):447-53. PubMed ID: 20870278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemically modified thrombin and anhydrothrombin that differentiate macromolecular substrates of thrombin.
    Hosokawa K; Ohnishi T; Kawakami A; Wakabayashi S; Koide T
    J Thromb Haemost; 2005 Dec; 3(12):2703-11. PubMed ID: 16246253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
    Wielders SJ; Bennaghmouch A; Reutelingsperger CP; Bevers EM; Lindhout T
    J Thromb Haemost; 2007 Mar; 5(3):571-6. PubMed ID: 17166251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New antithrombotic drugs.
    Gross PL; Weitz JI
    Clin Pharmacol Ther; 2009 Aug; 86(2):139-46. PubMed ID: 19553932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of thrombin into an anticoagulant by protein engineering.
    Gibbs CS; Coutré SE; Tsiang M; Li WX; Jain AK; Dunn KE; Law VS; Mao CT; Matsumura SY; Mejza SJ
    Nature; 1995 Nov; 378(6555):413-6. PubMed ID: 7477382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical role for thrombin in platelet aggregation under high shear stress.
    Sakurai Y; Shima M; Giddings J; Takeyama M; Kasuda S; Nogami K; Nishiya K; Yoshioka A
    Thromb Res; 2004; 113(5):311-8. PubMed ID: 15183043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
    Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation.
    Day JR; Haskard DO; Taylor KM; Landis RC
    Ann Thorac Surg; 2006 Feb; 81(2):619-24. PubMed ID: 16427862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects.
    Chackalamannil S
    J Med Chem; 2006 Sep; 49(18):5389-403. PubMed ID: 16942011
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of factor Xa and platelet aggregation.
    de Candia M; Liantonio F; Carotti A; De Cristofaro R; Altomare C
    J Med Chem; 2009 Feb; 52(4):1018-28. PubMed ID: 19193009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of an orally available PAR-1 antagonist as a novel antiplatelet agent.
    Lee S
    Arch Pharm Res; 2011 Apr; 34(4):515-7. PubMed ID: 21544715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic effects of the novel inhibitor of thrombin-induced offtelet aggregation and thrombus formation, 3-[2-[1,1':2',1"]-terphenyl-4'-yl)ethyl]phenoxyacetic acid.
    Miyamae T; Hashizume H; Ogawa T; Okayama T; Nukui E; Oshima K; Morikawa T; Hagiwara M
    Arzneimittelforschung; 1997 Jan; 47(1):13-8. PubMed ID: 9037437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy.
    Kuliopulos A; Covic L; Seeley SK; Sheridan PJ; Helin J; Costello CE
    Biochemistry; 1999 Apr; 38(14):4572-85. PubMed ID: 10194379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulant and antithrombotic action of the synthetic thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine nitrile.
    Kaiser B; Richter M; Hauptmann J; Markwardt F
    Pharmazie; 1991 Feb; 46(2):128-31. PubMed ID: 1852761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A laboratory method for parallel determination of platelet aggregation and thrombin generation.
    Köstenberger M; Gallistl S; Cvirn G; Muntean W
    Clin Lab; 2004; 50(1-2):41-8. PubMed ID: 15000219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.
    Andrade-Gordon P; Derian CK; Maryanoff BE; Zhang HC; Addo MF; Cheung Wm ; Damiano BP; D'Andrea MR; Darrow AL; de Garavilla L; Eckardt AJ; Giardino EC; Haertlein BJ; McComsey DF
    J Pharmacol Exp Ther; 2001 Jul; 298(1):34-42. PubMed ID: 11408522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease-activated receptor 1 antagonists prevent platelet aggregation and adhesion without affecting thrombin time.
    Nadal-Wollbold F; Bocquet A; Bourbon T; Létienne R; Le Grand B
    Eur J Pharmacol; 2010 Oct; 644(1-3):188-94. PubMed ID: 20655904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
    Chesebro JH; Webster MW; Zoldhelyi P; Roche PC; Badimon L; Badimon JJ
    Circulation; 1992 Dec; 86(6 Suppl):III100-10. PubMed ID: 1424043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G-protein-coupled receptors as signaling targets for antiplatelet therapy.
    Smyth SS; Woulfe DS; Weitz JI; Gachet C; Conley PB; Goodman SG; Roe MT; Kuliopulos A; Moliterno DJ; French PA; Steinhubl SR; Becker RC;
    Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):449-57. PubMed ID: 19023091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.